人脐带间充质干细胞治疗乙肝肝硬化失代偿期疗效观察  

Efficacy observation of mesenchymal stem cells derived from human umbilical cord for therapy of hepatitis B patients with decompensated cirrhosis

作　　者：骆海飞[1] 杨小安[1] 张卡[1] 舒欣[1] 曹红[1] 徐启桓[1] 

机构地区：[1]中山大学附属第三医院感染科,广州510630

出　　处：《中华实验和临床病毒学杂志》2015年第3期239-241,共3页Chinese Journal of Experimental and Clinical Virology

基　　金：广州市科技计划项目（2011Y1-00033-5）

摘　　要：目的 观察人脐带间充质干细胞治疗乙肝肝硬化失代偿期的短期疗效及安全性.方法 96例乙肝肝硬化失代偿期患者分为两组,治疗组50例在抗病毒、护肝、对症等内科综合治疗基础上通过外周静脉输注人脐带间充质干细胞,每周1次,连续输注4～6次1个疗程,对照组46例仅予抗病毒、护肝、对症等内科综合治疗.比较两组治疗后第2、4、6、12周的临床疗效及安全性.结果 治疗后4周,乏力、纳差、腹胀、水肿症状即较治疗前缓解,4 ～12周症状持续缓解,治疗12周后患者总体生存率为96％,其中2例患者分别在干细胞（UC-MSC）移植后8周及12周因肝性脑病死亡.两组在治疗第2、4、6、12周后ALT、AST、TB、ALB均有改善（P＜0.05）,其中治疗组治疗后ALB平均值高于对照组.治疗组4、8、12周后PT、PTA凝血指标较治疗前均有改善（P＜0.05）,而对照组治疗前后差异无统计学意义（P＞0.05）.治疗组干细胞治疗过程中,安全性良好,未出现严重不良发应.结论 人脐带间充质干细胞治疗失代偿期乙肝肝硬化短期内可改善患者凝血、白蛋白、肝功能及临床症状,且安全性良好,是一种值得推荐的替代治疗方法。Objective To investigate short-term efficacy and security of transplantation of human umbilical cord mesenchymal stem cells （HUCMSCs）in the course of treatment of decompensated cirrhosis.Methods Ninety-six Hepatitis B patients with decompensated cirrhosis were enrolled,among which 50 were sbject to transplantation of HUCMSCs in addition to routine therapy （the treatment group） and the rest patients were underwent routine therapy（the control group）.We observed the efficacy and security at 2,4,6 and 12 week of the treatment course.Results The symptoms of atigue,anorexia,bloating and edema were greatly relieved in both groups after 4 weeks,and sustained remission after 4-12 weeks.The overall survival rate was 96% after 12 weeks of the treatment group,2 patients were died after 8 and 12 weeks of the HUCMSCs transplantation due to hepatic encephalopathy repecticely.Compared to the baseline,ALT,AST,TBil and ALB（albumin） were improved after 2,4,6 and 12 weeks in both groups（P 〈 0.05）,and the averages of ALB（albumin） of treatment group were higher than the control group.PT（prothrombin time） and PTA（prothrombin time activity） were improved after 4,6,12 weeks in the treatment group （P 〈 0.05）,however,there were no differences in the control group during the 4,6 and 12 weeks（P 〉0.05）.During the course of HUCMSCs tranplantation,the security was satisfied and no special side effects were observed.Conclusion The transplantation of HUCMSCs for therapy of Hepatitis B patients with decompensated cirrhosis is a safety and effective therapy,and can improved ALB,PT,PTA,liver function and clinical symptoms within a short period,which is an alternative method of treatment recommended.

关 键 词：肝硬化 肝炎乙型 干细胞 治疗结果 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]